The stock of TherapeuticsMD Inc (NYSEMKT:TXMD) is a huge mover today! The stock decreased 2.19% or $0.15 during the last trading session, hitting $6.7. About 1.38M shares traded hands. TherapeuticsMD Inc (NYSEMKT:TXMD) has risen 9.78% since March 2, 2016 and is uptrending. It has outperformed by 1.52% the S&P500.
The move comes after 9 months negative chart setup for the $1.31 billion company. It was reported on Oct, 6 by Barchart.com. We have $6.10 PT which if reached, will make NYSEMKT:TXMD worth $117.90 million less.
Analysts await TherapeuticsMD Inc (NYSEMKT:TXMD) to report earnings on November, 2. They expect $-0.11 EPS, 0.00% or $0.00 from last year’s $-0.11 per share. After $-0.11 actual EPS reported by TherapeuticsMD Inc for the previous quarter, Wall Street now forecasts 0.00% EPS growth.
TherapeuticsMD Inc (NYSEMKT:TXMD) Ratings Coverage
Out of 3 analysts covering TherapeuticsMD (NYSEMKT:TXMD), 3 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. TherapeuticsMD has been the topic of 4 analyst reports since September 21, 2015 according to StockzIntelligence Inc. The company was maintained on Tuesday, December 8 by Stifel Nicolaus. Jefferies maintained the shares of TXMD in a report on Tuesday, December 8 with “Buy” rating. The company was maintained on Monday, September 21 by Jefferies.
According to Zacks Investment Research, “TherapeuticsMD, Inc. is a specialty pharmaceutical company focused on creating branded prescription, generic prescription and over-the-counter products targeted exclusively for women. It is developing three advanced hormone replacement products designed to alleviate the symptoms of and reduce the health risks resulting from menopause-related hormone deficiencies. TherapeuticsMD, Inc. is based in Boca Raton, Florida.”
Insitutional Activity: The institutional sentiment decreased to 1.25 in 2016 Q2. Its down 0.78, from 2.03 in 2016Q1. The ratio is negative, as 19 funds sold all TherapeuticsMD Inc shares owned while 29 reduced positions. 13 funds bought stakes while 47 increased positions. They now own 158.58 million shares or 4.25% more from 152.12 million shares in 2016Q1.
Rock Springs Cap Mngmt L P has 1.58 million shares for 0.99% of their US portfolio. Moreover, Eam Investors Ltd has 0.64% invested in TherapeuticsMD Inc (NYSEMKT:TXMD) for 502,820 shares. The Maryland-based Proshare Ltd Llc has invested 0% in TherapeuticsMD Inc (NYSEMKT:TXMD). Retail Bank Of Montreal Can has 0% invested in the company for 73,000 shares. Moreover, Massachusetts Com Ma has 0.01% invested in TherapeuticsMD Inc (NYSEMKT:TXMD) for 1.77M shares. Moreover, Legal And General Group Plc has 0% invested in TherapeuticsMD Inc (NYSEMKT:TXMD) for 41,455 shares. Ameritas Investment Prtn last reported 0.01% of its portfolio in the stock. Century Incorporated has invested 0% of its portfolio in TherapeuticsMD Inc (NYSEMKT:TXMD). Amer Gru last reported 86,402 shares in the company. Swiss Fincl Bank has invested 0% of its portfolio in TherapeuticsMD Inc (NYSEMKT:TXMD). Stoneridge Prns Ltd Liability last reported 0.59% of its portfolio in the stock. Moreover, Bancorp Of New York Mellon has 0.04% invested in TherapeuticsMD Inc (NYSEMKT:TXMD) for 15.73 million shares. Wellington Mngmt Grp Llp accumulated 0.05% or 23.74M shares. Deutsche Financial Bank Ag has 0% invested in the company for 161,339 shares. Analytic Investors Limited Liability reported 29,293 shares or 0% of all its holdings.
Another recent and important TherapeuticsMD Inc (NYSEMKT:TXMD) news was published by Fool.com which published an article titled: “Here’s Why TherapeuticsMD Inc. Fell 11.5% in August” on September 12, 2016.
TXMD Company Profile
TherapeuticsMD, Inc., incorporated on July 20, 2010, is a women’s healthcare product company. The Company’s segment is creating and commercializing products for women. The Firm is focused on conducting clinical trials necessary for regulatory approval and commercialization of advanced hormone therapy pharmaceutical products. The Company’s drug candidates used in its clinical trials are designed to alleviate the symptoms of and reduce the health risks resulting from menopause-related hormone deficiencies, including hot flashes, osteoporosis and vaginal discomfort. The Company’s drug candidates are created using its SYMBODA hormone technology, which enables the administration of hormones with high bioavailability alone or in combination. The Firm makes and distributes branded and generic prescription prenatal vitamins, as well as over-the-counter (OTC) vitamins.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.